

Table 1.

Summary of Articles Included in the Systematic Review<sup>a,b</sup>

Article	N	Age (mean ± SD, y)	Study Design/Sample Characteristics	Scale	Total IQ Result (mean ± SD)
Gold and Hurt (1990) <sup>13</sup>	19	24.26 ± 6.11	Clinical study with haloperidol treatment for 26 days/inpatients	WAIS	Before haloperidol treatment: 84.89 ± 12.17
Goldman et al (1993) <sup>14</sup>	40	Positive group: 27.8 ± 7.5 Negative group: 31.6 ± 9.9	Cross-sectional study with a full WAIS-R profile positive group and a negative group/inpatients	WAIS-R	Positive: 95.3 ± 13.5 Negative: 89.7 ± 18.0
Condray et al (1995) <sup>15</sup>	15	36.2 ± 8.8	Cross-sectional study with a healthy control group/inpatients admitted voluntarily to a research unit with duration of illness of 13.2 ± 8.9 y	WAIS-R	94.4 ± 6.9
Fujii et al (1997) <sup>16</sup>	10	31.9 ± 6.3	Clinical study with clozapine treatment; retesting with the same battery was conducted in a minimum of 1 year after the initial testing/chronic treatment-resistant inpatients	WAIS-R	Before clozapine treatment: 76.9 ± 9.4
Hawkins et al (1997) <sup>17</sup>	17	29.56 ± 9.29	Cross-sectional study with a schizophrenia spectrum disorders group and a mixed psychiatric group/not available	WAIS-R	87.19 ± 12.05
Mortimer and Bowen (1999) <sup>18</sup>	15	64 ± 17	Cross-sectional study/inpatients with duration of illness of 14 ± 16 y	WAIS-R	78 ± 9
Ilonen et al (2000) <sup>19</sup>	27	33.0 ± 13.6	Cross-sectional study with a healthy control group/first episode with no history of psychiatric inpatient treatment	WAIS-R	89.0 ± 19.4
Egan et al (2001) <sup>20</sup>	120	35.9 ± 8.2	Cross-sectional study with a sibling group and a healthy control group/not available	WAIS-R	92.6 ± 13.5
Baron and Hays (2003) <sup>21</sup>	49	Unclassified	Cross-sectional study/inpatients admitted at least twice within a 6-year period	WAIS-R	77.1 ± 12.6
Zakzanis et al (2003) <sup>22</sup>	32	58	Cross-sectional study with Alzheimer's disease patients as control group/late-onset outpatients diagnosed after age 45 y with an average illness duration of approximately 7 y	WAIS-III	81.84 ± 12.07
Nakano et al (2004) <sup>23</sup>	31	53 ± 10	Cross-sectional study/inpatients with duration of illness of 29 ± 10 y	WAIS-R	77 ± 16
Hori et al (2006) <sup>24</sup>	67	42.7 ± 11.9	Cross-sectional study with a healthy control group/chronic schizophrenia at stable dose for 3 mo	WAIS-R	87.7 ± 17.0
Maeda et al (2006) <sup>25</sup>	16	28.5 ± 4.2	Cross-sectional study/outpatients attending the psychiatric day treatment unit	WAIS-R	89.8 ± 13.1
Mo et al (2008) <sup>26</sup>	29	43.07 ± 8.83	Cross-sectional study with a healthy control group/inpatients in remission and duration of illness of 19.34 ± 7.82 y	WAIS-R	90.38 ± 12.85
Stefanopoulou et al (2009) <sup>27</sup>	36	34.88 ± 9.84	Clinical study without control group/inpatients with mean duration of illness of 12.4 y (range, 28 mo–28 y)	WAIS-III	73.41 ± 11.47
Ozguven, et al (2010) <sup>28</sup>	20	27 ± 4.75	Cross-sectional study with an Asperger's syndrome group and a healthy control group/outpatients	WAIS-R	87.9 ± 14.9
Lu et al (2012) <sup>29</sup>	112	25.2 ± 4.3	Cross-sectional study with a healthy control group/first-episode antipsychotic-naïve patients	WAIS-R	87.8 ± 14.7
Rapp et al (2012) <sup>30</sup>	124	Male: 32.3 ± 11.1 Female: 36.6 ± 9.6	Clinical study with control group with schizophrenia plus comorbidities/inpatients with a mean illness duration > 11 y for all groups	WAIS-R	Male: 83.6 ± 12.4 Female: 82.1 ± 13.1
Lin et al (2012) <sup>9</sup>	62	37.96 ± 9.83	Clinical study with control group/not available	WAIS-III	92.52 ± 15.63
Zhu et al (2013) <sup>31</sup>	526	28.150 ± 7.864	Cross-sectional study with a healthy control group/inpatients with mean duration of illness of 5.49 ± 7.21 y	WAIS-RC	Genotype AT+AA: 94.091 ± 15.485 Genotype TT: 97.935 ± 14.511
Kao et al (2013) <sup>32</sup>	39	Male: 40.08 ± 10.4 Female: 39.38 ± 10.89	Clinical study/outpatients in stable clinical condition	WAIS	Male: 88.64 ± 10.54 Female: 89.79 ± 12.56
Fukumoto et al (2014) <sup>33</sup>	63	Remission: 37.3 ± 11.8; No remission: 34.3 ± 13.8	Longitudinal study with 2 groups: a remission group and no remission group/outpatients with duration of illness of 10.4 ± 8.9 y (remission) and 9.8 ± 7.7 y (no remission)	WAIS-III	Remission group: 89.5 ± 16.4 No remission group: 82.7 ± 18.8
Dang et al (2014) <sup>34</sup>	17	Experiment group: 25.4 ± 2.9 Control group: 25.0 ± 2.8	Clinical study with 2 groups: patients with schizophrenia in an experiment group plus patients with schizophrenia in a control group/first episode on an inpatient unit	WAIS-R	Experiment group: 96.1 ± 5.8 Control group: 96.8 ± 5.0
El-Missiry et al (2015) <sup>35</sup>	109	32.2 ± 9.0	Cross-sectional study with a division of the N: adherent group and nonadherent group/outpatients	Arabic version of the WAIS	Adherent group: 98.73 ± 11.6 Nonadherent group: 81.58 ± 10.4
Nilsson et al (2016) <sup>36</sup>	23	32.0 ± 8.9	Clinical study with control group/inpatients with mean duration of illness of 7.5 ± 8.1 y	WAIS	79.4 ± 19.9
Liang et al (2016) <sup>37</sup>	288	Familial schizophrenia (FS): 23.29 ± 6.79 Sporadic schizophrenia (SS): 22.61 ± 6.15	Cross-sectional study using a group classification: FS plus SS plus control group and FS parents group plus SS parents group plus control group/first-episode patients with duration of illness of 19.83 ± 28.81 mo (FS) and 15.40 ± 22.44 mo (SS)	WAIS-R in China	FS group: 86.69 ± 13.84 SS group: 85.46 ± 15.35
Krukow et al (2017) <sup>38</sup>	47	27.02 ± 5.42	Cross-sectional study with a control group: healthy siblings/inpatients in the remission state with duration of illness of 5.29 ± 4.73 y	WAIS-R	90.33 ± 9.94
Kudo et al (2018) <sup>8</sup>	250	42.5 ± 14	Cross-sectional study with healthy control group/multiple groups including antipsychotic drug-free patients and treatment-resistant patients	WAIS-III	89.5 ± 19.0

<sup>a</sup>WAIS normative sample taken from Wechsler.<sup>12</sup><sup>b</sup>Extremely low: IQ ≤ 70, borderline: IQ between 70 and 79, low average: IQ between 80 and 89, average: IQ between 90 and 109, high average: IQ between 110 and 119, superior: IQ between 120 and 129, and very superior: IQ ≥ 130.

Abbreviations: IQ = intelligence quotient, WAIS = Wechsler Adult Intelligence Scale.